GlassScriptPhysician profile
Ralph M Hays
NPI 1528039922
$2,335.24
in general payments reported to CMS, 2019-2025
24 companies · $368 in 2025
The $368 reported for 2025 was more than what 79% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $663 · 2022: $449 · 2023: $468 · 2024: $388 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,223.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $721.50 | 2021-2025 | |
| Pfizer INC. | $239.72 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $139.95 | 2021-2023 | Verquvo |
| Esperion Therapeutics, INC. | $120.43 | 2021 | |
| Amarin Pharma, INC. | $112.06 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.62 | 2021-2025 | Jardiance |
| Abiomed | $100.67 | 2022-2023 | Impella |
| Astrazeneca Pharmaceuticals LP | $98.83 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $92.94 | 2021-2022 | |
| Boston Scientific Corporation | $91.75 | 2022-2025 | Watchman, Watchman Flx |
| Amgen INC. | $56.93 | 2021-2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.28 | 2024-2025 | Lifevest |
| Scpharmaceuticals INC. | $49.85 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $48.85 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $46.88 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $44.14 | 2025 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $40.59 | 2023 | Opsumit |
| Silk Road Medical, INC. | $39.98 | 2021-2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Kiniksa Pharmaceuticals, LTD. | $39.15 | 2021-2023 | Arcalyst |
| Abbott Laboratories | $24.49 | 2021 | |
| Lilly USA, LLC | $19.26 | 2025 | Zepbound, Mounjaro |
| Cleerly, INC. | $18.43 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Lexicon Pharmaceuticals, INC. | $17.12 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $13.82 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Hays listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.